Analysts Set Annexon, Inc. (NASDAQ:ANNX) Price Target at $15.80

Annexon, Inc. (NASDAQ:ANNX) has been assigned an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $15.80.

A number of research firms have weighed in on ANNX. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Annexon in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Annexon in a report on Tuesday, December 17th.

Hedge Funds Weigh In On Annexon

A number of large investors have recently modified their holdings of the company. Parkman Healthcare Partners LLC lifted its holdings in shares of Annexon by 0.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock worth $1,945,000 after purchasing an additional 1,768 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Annexon by 1.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock worth $945,000 after purchasing an additional 2,450 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after purchasing an additional 3,355 shares in the last quarter. E Fund Management Co. Ltd. lifted its holdings in shares of Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after purchasing an additional 4,086 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Annexon by 6.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company’s stock worth $325,000 after purchasing an additional 4,092 shares in the last quarter.

Annexon Trading Up 2.8 %

Shares of NASDAQ ANNX opened at $2.60 on Thursday. The company has a market cap of $285.25 million, a price-to-earnings ratio of -2.48 and a beta of 1.14. Annexon has a 12 month low of $2.30 and a 12 month high of $8.40. The stock has a 50-day moving average price of $3.49 and a two-hundred day moving average price of $5.21.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, sell-side analysts predict that Annexon will post -0.96 earnings per share for the current year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.